Understanding the relationship between semaglutide and dermatological reactions is important for safe medication use
Key Takeaway: The .25 mg dose is designed to help your body adjust to the medication safely, setting a foundation for higher doses later in your treatment program
One-week washout, then start tirzepatide at a mid-range dose
For obesity, it is marketed under the brand name Wegovy
People commonly experience some or all of the following side effects after stopping GLP-1 medications, says Goddard: Increased hunger (often noticeably stronger) Food noise, often described as the persistent mental chatter about eating and cravings Weight regain, which research shows can begin within weeks Changes in blood sugar control, particularly for people with type 2 diabetes Loss of some cardiometabolic benefits gained during treatment Improvement in GLP-1-related side effects such as nausea, constipation and bloating Not everyone experiences every one of these changes, and their severity varies widely
Wegovy, the branded form of semaglutide, follows a stepwise dose escalation protocol that peaks at 2.4 mg per week